Evidence map›Paper›PMID 42008572›Full record

ArticlePLoS pathogens2026

Entry, replication and innate immunity evasion of BANAL-236, a SARS-CoV-2-related bat virus, in Rhinolophus and human cells.

Ségolène Gracias, Elodie Le Seac'h, Samuel Donaire-Carpio, Françoise Vuillier, Léa Vendramini, Adam Moundib, Sarah Temmam, Magdalena Rutkowska, Flora Donati, Anastasija Cupic and 14 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Ségolène GraciasInstitut Pasteur, Université Paris Cité, CNRS UMR 3569, Virus sensing and signaling Unit, Paris, France.
Elodie Le Seac'hInstitut Pasteur, Université Paris Cité, CNRS UMR 3569, Virus sensing and signaling Unit, Paris, France.
Samuel Donaire-CarpioInstitut Pasteur, Université Paris Cité, CNRS UMR 3569, Virus sensing and signaling Unit, Paris, France.
Françoise VuillierInstitut Pasteur, Université Paris Cité, Interactomics, RNA and Immunity Unit, Paris, France.
Léa VendraminiInstitut Pasteur, Université Paris Cité, CNRS UMR 3569, Virus sensing and signaling Unit, Paris, France.
Adam MoundibInstitut Pasteur, Université Paris Cité, CNRS UMR 3569, Virus sensing and signaling Unit, Paris, France.
Sarah TemmamInstitut Pasteur, Université Paris Cité, Pathogen Discovery Laboratory, Paris, France.
Magdalena RutkowskaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Flora DonatiInstitut Pasteur, National Reference Center for Respiratory Viruses, Paris, France.
Anastasija CupicDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Javier JusteEstación biológica de doñana, Avda, Seville, and CIBER Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Carles Martinez-RomeroDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Nathalie MorelDépartement Médicaments et Technologies pour la Santé (DMTS), Service de Pharmacologie et Immunoanalyse, Université Paris Saclay, CEA, INRA, Gif-sur Yvette, France.
Olivier SchwartzInstitut Pasteur, Université Paris Cité, Virus and Immunity Unit, Paris, France.
Nevan J KroganQuantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, California United States of America.
Lisa MiorinDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Marcel A MüllerInstitute of Virology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Caroline DemeretInstitut Pasteur, Université Paris Cité, Interactomics, RNA and Immunity Unit, Paris, France.
Sandie MunierInstitut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, Paris, France.
Philippe RoingeardINSERM U1259 MAVIVH and INSERM US61, Université de Tours and CHU de Tours, Tours, France.
Jyoti BatraQuantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, California United States of America.
Adolfo Garcia-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Vincent CavalInstitut Pasteur, Université Paris Cité, CNRS UMR 3569, Virus sensing and signaling Unit, Paris, France.
Nolwenn JouvenetInstitut Pasteur, Université Paris Cité, CNRS UMR 3569, Virus sensing and signaling Unit, Paris, France.ORCID 0000-0001-6103-6048

Funding

SARS-CoV adaptations through a Systems Biology Lens (SYBIL)U19AI135972 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Adolfo Garcia-Sastre · 2018 to 2026
$27.2M
NIH HHS U19AI135972
6 · The paper itself

Abstract

Asian Rhinolophus bats are considered the natural reservoirs of an ancestral SARS-CoV-2. However, the biology of SARS-CoV-2-related viruses in bat cells is not well understood. Here, we investigated the replication of an isolate of BANAL-236, the only bat-derived SARS-CoV-2 relative isolated to date, in Rhinolophus ferrumequinum lungs (Rfe) cells. BANAL-236 did not replicate in wild-type Rhinolophus cell lines. Entry assays using pseudoviruses expressing the spike proteins (S) of SARS-CoV-2, BANAL-236, and BANAL-52 revealed that efficient S-mediated entry depends on the expression of human ACE2 (hACE2) and human TMPRSS2 (hTMPRSS2) in human and Rhinolophus cells. Through biochemical, virological, and electron microscopy analyses, we showed that BANAL-236 and SARS-CoV-2 completed their replication cycles in RFe cells engineered to express high levels of hACE2 and hTMPRSS2. Despite efficient viral replication in modified Rhinolophus and human cells, no induction of interferon (IFN)-stimulated genes was detected. Using a screening approach, we identified several BANAL-236 proteins that antagonize IFN production and signalling in human cells. Our findings thus show that BANAL-236 possesses critical features that enabled zoonotic spillover: hACE2 usage and potent evasion of human IFN responses. The Rhinolophus cellular model we established offers a platform for further investigating the interactions between bat sarbecoviruses and their reservoir hosts.

Indexed as

ChiropteraImmune EvasionImmunity, InnateSARS-CoV-2Virus InternalizationVirus ReplicationAngiotensin-Converting Enzyme 2AnimalsCell LineCOVID-19HumansSerine EndopeptidasesSpike Glycoprotein, CoronavirusACE2 protein, humanAngiotensin-Converting Enzyme 2Serine EndopeptidasesSpike Glycoprotein, CoronavirusTMPRSS2 protein, human

Identifiers

PMID42008572
PMCPMC13108884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.